Sponsor content

Groundbreaking, noninvasive tests for bladder cancer

Pacific Edge has expanded the international market for two new molecular tests that provide better detection and management of urothelial cancer. To download the full article, please sign in.

Go to the profile of Pacific Edge
Nov 11, 2015
0
Page of
Go to the profile of Pacific Edge

Pacific Edge

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specializing in the discovery and commercialization of diagnostic and prognostic tests for better detection and monitoring of cancer. The company is developing and commercializing its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies. Pacific Edge has two proprietary, novel, accurate, molecular diagnostic products in-market providing more accurate, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company’s dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia and has initiated launch in the USA in July 2015.

Comments are disabled